vimarsana.com
Home
Live Updates
Novavax: Prototype NVX-CoV2373 Achieves Pre-specified Immuno
Novavax: Prototype NVX-CoV2373 Achieves Pre-specified Immuno
Novavax: Prototype NVX-CoV2373 Achieves Pre-specified Immunologic Endpoint In PREVENT-19 Trial
WASHINGTON (dpa-AFX) - Novavax, Inc. (NVAX) reported data from the phase 3 PREVENT-19 trial and Study 307. PREVENT-19 data in both adults aged 18 and older and adolescents aged 12 through 17 showed
Related Keywords
Washington ,
United States ,
Gregory Glenn ,
More Such Health News ,
Novavax Inc ,
Novavax ,
Prototype ,
Ov2373 ,
Chieves ,
Enspecified ,
Immunologic ,
Ndpoint ,
Prevent ,
Trial ,